ClinicalTrials.Veeva

Menu

MRI Compared to PET/CT for Staging and Treatment Response in Lymphoma

G

Guangxi Medical University

Status

Unknown

Conditions

Lymphoma

Treatments

Radiation: fludeoxyglucose F 18
Device: positron emission tomography/computed tomography
Device: magnetic resonance imaging

Study type

Interventional

Funder types

Other

Identifiers

NCT02733887
PET-MRI/lymphoma

Details and patient eligibility

About

The lymph nodes or masses,positron emission tomography/computed tomography (PET/CT) standardized uptake values(SUV) results, whole body magnetic resonance imaging(MRI) intravoxel incoherent motion(IVIM) sequence D, D*, f values and MRI volumes of lymphoma patients were compared before and after the chemotherapy in this project prospectively to provide data for evaluating the dependency and differences of PET/CT and whole body MRI in lymphoma staging and therapeutic evaluation. Long-term therapeutic effect indexes obtained in follow-up visits of patients such as Overall Survival(OS), Progression Free Survival (PFS) etc. were used to evaluate the diagnostic sensitivity and differences of MRI and PET/CT. The research could provide a new method of nonionizing radiation iconography for physicians to give appropriate treatments and predict prognosis.

Enrollment

66 estimated patients

Sex

All

Ages

8 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Lymphoma subtypes were diagnosed on the basis of tissue samples obtained by biopsy or surgery according to the criteria outlined in the current World Health Organization (WHO) classification of hematologic and lymphoid malignancies, by a reference pathologist.
  • Patients who gave written informed consent were referred for DWI-MRI and 18F-FDG-PET/CT.
  • Stable physical medical conditions (patients conscious and comfortable, scheduled for an elective diagnostic imaging).

Exclusion criteria

  • Pregnancy, general contraindications to MRI, and therapeutic interventions between DWI-MRI and 18F-FDG-PET/CT were used.

Trial design

Primary purpose

Diagnostic

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

66 participants in 1 patient group

lymphoma
Experimental group
Description:
The lymph nodes or masses, fludeoxyglucose F18 positron emission tomography/computed tomography(PET/CT) standard uptake value(SUV) results, whole body magnetic resonance imaging(MRI) intravoxel incoherent motion(IVIM) sequence D, D\*,f values and MRI volumes of lymphoma were compared before and after the chemotherapy in this project prospectively to provide data for evaluating the dependency and differences of PET/CT and whole body MRI in lymphoma staging and therapeutic evaluation.
Treatment:
Device: magnetic resonance imaging
Device: positron emission tomography/computed tomography
Radiation: fludeoxyglucose F 18

Trial contacts and locations

1

Loading...

Central trial contact

Chengcheng Liao, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems